share_log

Virpax Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

SEC announcement ·  Jan 2 13:00
Summary by Futu AI
On December 31, 2023, a filing was made with the United States Securities and Exchange Commission (SEC) by Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz, indicating that they do not hold any shares of Virpax Pharmaceuticals, Inc. The Schedule 13G/A amendment filing, which is a requirement for certain levels of ownership in a company, shows that these entities and individuals have ceased to be the beneficial owners of more than five percent of Virpax Pharmaceuticals' common stock. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934. Sabby Management, LLC, based in Delaware, and Hal Mintz, a U.S. citizen, are associated with the Cayman Islands-based Sabby Volatility Warrant Master Fund, Ltd. The filing includes a certification that the securities were not acquired for the purpose of changing or influencing the control of Virpax Pharmaceuticals and were not held in connection with any transaction having that purpose or effect. The joint filing agreement was dated January 2, 2024.
On December 31, 2023, a filing was made with the United States Securities and Exchange Commission (SEC) by Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz, indicating that they do not hold any shares of Virpax Pharmaceuticals, Inc. The Schedule 13G/A amendment filing, which is a requirement for certain levels of ownership in a company, shows that these entities and individuals have ceased to be the beneficial owners of more than five percent of Virpax Pharmaceuticals' common stock. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934. Sabby Management, LLC, based in Delaware, and Hal Mintz, a U.S. citizen, are associated with the Cayman Islands-based Sabby Volatility Warrant Master Fund, Ltd. The filing includes a certification that the securities were not acquired for the purpose of changing or influencing the control of Virpax Pharmaceuticals and were not held in connection with any transaction having that purpose or effect. The joint filing agreement was dated January 2, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.